New molecular targets for treatment of lymphoma.
In recent years, several molecular mechanisms involved in promoting cancer cell survival and growth have been identified. These discoveries helped in designing and testing novel drugs that target specific cellular pathways. In this review, we focus on new molecular targets that are being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA.
Barbara
B
Pro
Anas
A
Younes
D000970:Antineoplastic Agents / Q000494:pharmacology; D049109:Cell Proliferation; D002470:Cell Survival; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008223:Lymphoma / Q000235:genetics* / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D008954:Models, Biological; D008957:Models, Genetic; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D012074:Remission Induction; D013792:Thalidomide / Q000494:pharmacology
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D018124:Receptors, Tumor Necrosis Factor; D013792:Thalidomide; D046988:Proteasome Endopeptidase Complex